Real-time Estimate
Cboe Europe
09:03:43 27/06/2024 BST
|
5-day change
|
1st Jan Change
|
921.5
CHF
|
-0.16%
|
|
-2.13%
|
+7.04%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,954
|
2,705
|
3,720
|
2,605
|
3,651
|
3,959
|
-
|
-
|
Enterprise Value (EV)
1 |
2,064
|
2,790
|
4,127
|
3,024
|
4,039
|
4,314
|
4,269
|
4,175
|
P/E ratio
|
37.4
x
|
45.9
x
|
40.4
x
|
16.9
x
|
32.8
x
|
26.7
x
|
22.9
x
|
20.1
x
|
Yield
|
0.6%
|
0.46%
|
0.36%
|
0.55%
|
0.42%
|
0.41%
|
0.43%
|
0.46%
|
Capitalization / Revenue
|
2.34
x
|
3.2
x
|
3.37
x
|
2.12
x
|
2.87
x
|
3.04
x
|
2.79
x
|
2.58
x
|
EV / Revenue
|
2.48
x
|
3.3
x
|
3.74
x
|
2.46
x
|
3.18
x
|
3.32
x
|
3.01
x
|
2.72
x
|
EV / EBITDA
|
14.7
x
|
18.7
x
|
19.9
x
|
11.1
x
|
14.8
x
|
15.1
x
|
13.3
x
|
11.6
x
|
EV / FCF
|
544
x
|
60.6
x
|
621
x
|
111
x
|
56.2
x
|
96.6
x
|
68.2
x
|
63.7
x
|
FCF Yield
|
0.18%
|
1.65%
|
0.16%
|
0.9%
|
1.78%
|
1.03%
|
1.47%
|
1.57%
|
Price to Book
|
2.78
x
|
3.72
x
|
5.44
x
|
3.35
x
|
4.35
x
|
3.99
x
|
3.51
x
|
3.04
x
|
Nbr of stocks (in thousands)
|
4,167
|
4,151
|
4,182
|
4,247
|
4,247
|
4,289
|
-
|
-
|
Reference price
2 |
469.0
|
651.5
|
889.5
|
613.5
|
859.5
|
923.0
|
923.0
|
923.0
|
Announcement Date
|
04/03/20
|
24/02/21
|
25/02/22
|
22/02/23
|
20/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
833.5
|
845.1
|
1,102
|
1,230
|
1,272
|
1,301
|
1,418
|
1,533
|
EBITDA
1 |
140.7
|
149.4
|
207.2
|
272.5
|
273.3
|
286.5
|
321.8
|
360.2
|
EBIT
1 |
89.15
|
94.3
|
124.4
|
190.8
|
191.9
|
200.6
|
227.5
|
259.2
|
Operating Margin
|
10.7%
|
11.16%
|
11.28%
|
15.52%
|
15.09%
|
15.42%
|
16.04%
|
16.9%
|
Earnings before Tax (EBT)
1 |
51.43
|
74.03
|
126.5
|
218.8
|
150.4
|
189.7
|
219.8
|
245.4
|
Net income
1 |
53.15
|
60.87
|
95.6
|
156.5
|
112.8
|
147.9
|
172.8
|
197.6
|
Net margin
|
6.38%
|
7.2%
|
8.67%
|
12.73%
|
8.87%
|
11.37%
|
12.18%
|
12.89%
|
EPS
2 |
12.53
|
14.18
|
22.03
|
36.28
|
26.22
|
34.57
|
40.27
|
46.00
|
Free Cash Flow
1 |
3.797
|
46
|
6.649
|
27.25
|
71.81
|
44.64
|
62.62
|
65.5
|
FCF margin
|
0.46%
|
5.44%
|
0.6%
|
2.22%
|
5.65%
|
3.43%
|
4.41%
|
4.27%
|
FCF Conversion (EBITDA)
|
2.7%
|
30.79%
|
3.21%
|
10%
|
26.28%
|
15.58%
|
19.46%
|
18.18%
|
FCF Conversion (Net income)
|
7.14%
|
75.58%
|
6.96%
|
17.41%
|
63.68%
|
30.18%
|
36.24%
|
33.14%
|
Dividend per Share
2 |
2.800
|
3.000
|
3.200
|
3.400
|
3.600
|
3.790
|
3.980
|
4.275
|
Announcement Date
|
04/03/20
|
24/02/21
|
25/02/22
|
22/02/23
|
20/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019 S2
|
2020 S1
|
2020 S2
|
2021 S1
|
2021 S2
|
2022 S1
|
2022 S2
|
2023 S1
|
2023 S2
|
2024 S1
|
2024 S2
|
---|
Net sales
|
439.6
|
388.1
|
457
|
466.9
|
635.5
|
586.7
|
642.8
|
607.1
|
664.4
|
-
|
-
|
EBITDA
1 |
74.41
|
58.06
|
91.35
|
80.55
|
126.7
|
130.2
|
142.3
|
125.7
|
147.6
|
130
|
152
|
EBIT
1 |
47.15
|
31.27
|
63.03
|
40.37
|
84.03
|
91.4
|
99.4
|
87.2
|
104.7
|
88
|
107
|
Operating Margin
|
10.73%
|
8.06%
|
13.79%
|
8.65%
|
13.22%
|
15.58%
|
15.46%
|
14.37%
|
15.76%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-
|
38.15
|
88.38
|
83.62
|
135.2
|
-
|
75.52
|
79
|
101
|
Net income
1 |
22.18
|
20.66
|
40.2
|
29.29
|
66.31
|
62.74
|
93.74
|
55.21
|
57.56
|
62
|
79
|
Net margin
|
5.05%
|
5.33%
|
8.8%
|
6.27%
|
10.43%
|
10.69%
|
14.58%
|
9.1%
|
8.66%
|
-
|
-
|
EPS
2 |
5.240
|
4.860
|
9.320
|
6.770
|
15.26
|
14.51
|
21.77
|
12.99
|
13.23
|
14.20
|
18.00
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
04/03/20
|
20/08/20
|
24/02/21
|
19/08/21
|
25/02/22
|
18/08/22
|
22/02/23
|
22/08/23
|
20/02/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
110
|
85.5
|
407
|
419
|
389
|
355
|
310
|
216
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
0.7784
x
|
0.5725
x
|
1.964
x
|
1.536
x
|
1.422
x
|
1.239
x
|
0.9635
x
|
0.6003
x
|
Free Cash Flow
1 |
3.8
|
46
|
6.65
|
27.2
|
71.8
|
44.6
|
62.6
|
65.5
|
ROE (net income / shareholders' equity)
|
7.76%
|
8.54%
|
13.5%
|
21.2%
|
15.7%
|
16.2%
|
16.5%
|
16.3%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
7.02%
|
7.73%
|
8.21%
|
8.79%
|
Assets
1 |
-
|
-
|
-
|
-
|
1,607
|
1,914
|
2,105
|
2,248
|
Book Value Per Share
2 |
168.0
|
175.0
|
163.0
|
183.0
|
198.0
|
231.0
|
263.0
|
304.0
|
Cash Flow per Share
2 |
15.50
|
26.70
|
27.60
|
33.00
|
49.20
|
74.00
|
66.60
|
71.80
|
Capex
1 |
61.6
|
68.8
|
113
|
104
|
127
|
191
|
169
|
174
|
Capex / Sales
|
7.39%
|
8.14%
|
10.26%
|
8.42%
|
10.02%
|
14.67%
|
11.88%
|
11.32%
|
Announcement Date
|
04/03/20
|
24/02/21
|
25/02/22
|
22/02/23
|
20/02/24
|
-
|
-
|
-
|
Average target price
1,016
CHF Spread / Average Target +10.07% Consensus |
1st Jan change
|
Capi.
|
---|
| +7.04% | 4.41B | | +54.61% | 811B | | +43.79% | 640B | | -6.33% | 353B | | +20.62% | 333B | | +10.44% | 302B | | +18.00% | 246B | | +2.62% | 225B | | +12.76% | 218B | | +8.61% | 168B |
Other Pharmaceuticals
|